MOMA Therapeutics Appoints Susan Pandya, M.D., to Board of Directors and Expands Management Team [Yahoo! Finance]
Agios Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Corporate Development & Strategy Officer
Agios to Present at Upcoming Investor Conferences
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $58.00 price target on the stock.
Agios to Present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025